[Form 8-K Filing: Financial Guidance Update](index=1&type=section&id=Form%208-K%20Filing%20April%203%2C%202025) This Form 8-K filing provides an update on preliminary Q1 2025 financial results, revised EPS guidance due to an IPR&D expense, and details related exhibits [Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) AbbVie announced preliminary Q1 2025 results, highlighting an expected acquired In-Process Research and Development (IPR&D) and milestones expense of $248 million, consequently updating its full-year and Q1 2025 adjusted diluted EPS guidance to incorporate this impact, while noting that the results are not yet final - Preliminary Q1 2025 results are expected to include a pre-tax acquired IPR&D and milestones expense of **$248 million**, which will unfavorably impact both GAAP and adjusted non-GAAP diluted EPS by **$0.13**[5](index=5&type=chunk) Updated 2025 Adjusted Diluted EPS Guidance | Guidance Period | Updated Adjusted Diluted EPS Range | Notes | | :--- | :--- | :--- | | Q1 2025 | $2.34 - $2.38 | Includes $0.13/share impact from IPR&D expense | | Full-Year 2025 | $11.99 - $12.19 | Includes Q1 IPR&D expense; original guidance from Jan 31, 2025 excluded this | - The updated guidance does not reflect the impact from the licensing agreement with Gubra for GUB014295, as that transaction closed after the first quarter of 2025[6](index=6&type=chunk) [Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) The report includes Exhibit 99.1, which provides detailed guidance including the impact of the acquired IPR&D and milestones expense, and Exhibit 104 for XBRL data - The filing includes the following key exhibits: * **Exhibit 99.1:** Detailed guidance including the impact of acquired IPR&D and milestones expense * **Exhibit 104:** Cover page data formatted in Inline XBRL[10](index=10&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) The report contains forward-looking statements subject to risks and uncertainties, with AbbVie cautioning that actual results may differ materially and directing investors to its Form 10-K and other SEC filings for a detailed discussion of these risks, without undertaking an obligation to update these statements - Forward-looking statements are subject to risks including, but not limited to, challenges to intellectual property, competition, R&D difficulties, adverse litigation or government action, and changes in laws and regulations[9](index=9&type=chunk) - For more detailed information on risks and uncertainties, the company refers to Item 1A, 'Risk Factors,' of its 2024 Annual Report on Form 10-K and subsequent SEC filings[9](index=9&type=chunk)

Core Insights - AbbVie reported strong first-quarter results for 2025, exceeding expectations and indicating a solid start to the year, with a focus on pipeline advancements and strategic investments [2][3] Financial Performance - First-quarter diluted EPS was $0.72 on a GAAP basis, a decrease of 6.5%, while adjusted diluted EPS was $2.46, an increase of 6.5% [3][19] - Net revenues for the first quarter reached $13.343 billion, an increase of 8.4% on a reported basis and 9.8% on an operational basis [3][4] - The immunology portfolio generated global net revenues of $6.264 billion, up 16.6% on a reported basis and 18.1% operationally [3][4] - Skyrizi net revenues were $3.425 billion, reflecting a 70.5% increase on a reported basis, while Rinvoq net revenues were $1.718 billion, up 57.2% [4][19] - Humira net revenues decreased by 50.6% to $1.121 billion [4][19] - Neuroscience portfolio revenues were $2.282 billion, an increase of 16.1% [4][19] - Oncology portfolio revenues reached $1.633 billion, up 5.8% [4][19] - Aesthetics portfolio revenues were $1.102 billion, a decrease of 11.7% [4][19] Guidance and Outlook - AbbVie raised its 2025 adjusted diluted EPS guidance from $11.99 - $12.19 to $12.09 - $12.29, accounting for an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense [3][9] Recent Developments - The European Commission granted marketing authorization to Rinvoq for treating giant cell arteritis in adults, marking the eighth approved indication for the drug in the EU [7] - AbbVie announced a collaboration with Xilio Therapeutics to develop novel immunotherapies for cancer [7] - A Biologics License Application was submitted to the FDA for trenibotulinumtoxinE for treating moderate to severe glabellar lines, which could be the first neurotoxin of its kind available [7][8]

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering documents omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, is accused of acquiring shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were affected by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, is accused of acquiring shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest [3]. Group 2: Financial Implications - AbbVie announced its agreement to acquire Cerevel for $45 per share on December 6, 2023, resulting in Bain Capital receiving over $120 million in windfall profits from shares purchased at the depressed offering price [3]. - Cerevel's January 18, 2024, Proxy statement allegedly misled investors regarding the timing and nature of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - AbbVie has submitted a Biologics License Application (BLA) to the FDA for TrenibotulinumtoxinE (TrenibotE), a first-in-class neurotoxin for treating moderate to severe glabellar lines, characterized by rapid onset and shorter duration of effect [2][4]. Group 1: Product Overview - TrenibotE is a first-in-class botulinum neurotoxin serotype E with a rapid onset of action as early as 8 hours post-administration and a shorter duration of effect lasting 2-3 weeks [1][4]. - If approved, TrenibotE will be the first neurotoxin of its kind available to patients, providing a new option in the aesthetic treatment landscape [1][3]. Group 2: Clinical Data - The BLA submission is supported by data from over 2,100 patients treated with TrenibotE in clinical trials, including two pivotal Phase 3 studies (M21-500 and M21-508) and a Phase 3 open-label safety study (M21-509) [4]. - All primary and secondary endpoints of the Phase 3 studies were met, demonstrating efficacy and safety comparable to placebo, with treatment-emergent adverse events similar to those observed in placebo groups [4]. Group 3: Market Implications - TrenibotE has the potential to transform the aesthetic toxin treatment landscape, particularly for new patients who may have concerns about looking unnatural with neurotoxin treatments [3][5]. - The introduction of TrenibotE may empower patients to explore aesthetic treatments with greater confidence, addressing barriers to initiating neurotoxin use [5].

Market Overview - US stock index futures are all down, with Dow futures down 0.47%, S&P 500 futures down 0.31%, and Nasdaq futures down 0.26% [1] - European indices also show declines, with Germany's DAX down 0.07%, UK's FTSE 100 down 0.04%, France's CAC40 down 0.14%, and the Euro Stoxx 50 down 0.18% [2] - WTI crude oil increased by 1.25% to $63.05 per barrel, while Brent crude rose by 1.03% to $66.80 per barrel [2] US Stock Market Insights - Jefferies highlights a critical point for the S&P 500 index at 5500, which needs to be breached to recover from a 19% drop since February's historical high [3] - Christopher Wood from Jefferies suggests that the golden era for US stocks is over, predicting further declines in US equities, bonds, and the dollar [5] Automotive Industry - Japanese automakers saw a surge in US sales in March, with Toyota's sales up 8% to 231,336 units, Honda's up 13%, and Nissan's up 10% [4] Company Earnings Reports - Merck's Q1 earnings exceeded expectations with sales of $15.5 billion, although they anticipate a $200 million loss due to tariffs by 2025 [9] - American Airlines withdrew its 2025 profit guidance, reporting a Q1 net loss of $473 million, worsened by tariff pressures and government spending uncertainties [9] - Procter & Gamble lowered its annual organic sales growth forecast from 3%-5% to 2% due to tariff pressures and fluctuating consumer demand [10] - Sanofi's Q1 earnings surpassed expectations, driven by strong demand for its Dupixent drug, with sales of €9.89 billion [10] - IBM reported Q1 sales of $14.5 billion, exceeding expectations, but concerns remain regarding the impact of tariffs and government spending cuts on business [11] - Texas Instruments provided a positive Q2 earnings outlook, with expected revenue between $4.17 billion and $4.53 billion, driven by improved demand in industrial and automotive sectors [12] Technology Sector - Google Chrome's potential market value is estimated at over $50 billion, according to competitors, amid ongoing antitrust scrutiny [13] - TSMC plans to begin production using A14 chip technology in 2028, aiming to maintain its leadership in the semiconductor industry [13]

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its stock offering and the subsequent acquisition by AbbVie Inc. [1][3] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [2]. - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [4]. Group 2: Allegations Against Cerevel - The lawsuit claims that Cerevel's October 16, 2023, secondary stock offering omitted critical information about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding $120 million when AbbVie announced the acquisition at $45 per share [3]. Group 3: Legal Representation - The Gross Law Firm is representing the shareholders in this class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [5].

Due to the essentiality of healthcare, the medical sector can provide a defensive hedge against market uncertainty, and investors may be eyeing AbbVie (ABBV)  and HCA Healthcare (HCA)  stock ahead of their Q1 reports on Friday, April 25.Being the largest non-governmental operator of acute care hospitals in the United States, HCA shares are up a very respectable +11% year to date, with pharmaceutical giant AbbVie’s stock virtually flat but outperforming the benchmark S&P 500’s 10% decline as well. That said, ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][4] Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes shareholders who sold or held shares during this timeframe [3]. - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [5]. Group 2: Allegations Against Cerevel - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [4]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [4]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [6].

Core Viewpoint - AbbVie is expected to report first-quarter 2025 earnings on April 25, with sales estimated at $12.91 billion and earnings at $2.40 per share, although earnings estimates have declined recently [1][6]. Financial Performance - AbbVie has a history of exceeding earnings expectations, with a trailing four-quarter average earnings surprise of 2.37% and a recent surprise of 1.41% [1]. - The company anticipates adjusted earnings between $2.34 and $2.38 per share and net revenues of approximately $12.8 billion for the upcoming quarter [6]. Revenue Drivers - Sales growth is expected to be driven by newer immunology drugs, Skyrizi and Rinvoq, with consensus estimates for their sales at $3.19 billion and $1.61 billion, respectively [7]. - The immunology franchise is projected to generate $6.1 billion in revenues, including $3.2 billion from Skyrizi, $1.6 billion from Rinvoq, and $900 million from U.S. Humira [9]. Challenges - AbbVie has faced sales erosion following the loss of patent protection for Humira, with consensus estimates for its sales at $1.32 billion [8]. - The oncology segment is expected to generate $1.5 billion, with Imbruvica sales declining due to competition, estimated at $676 million [10]. Neuroscience and Aesthetics Segments - Neuroscience sales are projected at $2.1 billion, driven by products like Botox Therapeutic and Vraylar, with consensus estimates at $2.16 billion [13]. - Aesthetics sales are expected to be impacted by sluggish growth in Botox and Juvederm, with estimates at $1.14 billion [14]. Stock Performance and Valuation - AbbVie shares have declined 2% year-to-date, outperforming the industry and S&P 500 [16]. - The stock trades at a price/earnings ratio of 13.58, slightly below the industry average of 14.89, but above its five-year mean of 12.06 [19]. Long-term Outlook - AbbVie is well-positioned for growth despite challenges, with strong sales from Skyrizi and Rinvoq, and a proactive approach to pipeline development [21][22]. - The company has entered the obesity treatment market, indicating strategic expansion [23]. - Despite some declining estimates, the solid pipeline and growth prospects for 2025 sales and profits suggest a reason to remain invested in AbbVie stock [24].